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Pivotal registration clinical trials are almost always
the keys in determining whether a medical product
under testing is ready for marketing. Therefore,
planning such a trial is critical to its success. It is
well known that planning such trials requires very
careful consideration of many design specifica-
tions, such as primary endpoint(s), key second-
ary endpoint(s), effect sizes of the test medical
product, doses of the test drug, nuisance parame-
ters, dropouts, management of missing data, non-
compliance, and statistical assumptions underlying
design and analysis. As these specifications are
often unknown before designing a pivotal registra-
tion trial, difficulties with trial planning will al-
ways arise. In regulatory applications, we have, in
the past decade at least, seen a high probability
of failure of such pivotal registration trials.
In regulatory practice, many types of design
adjustments are made during the course of any
pivotal registration. The adjustments are mostly
made known to regulatory agencies in the form
of so-called protocol amendments. Many of the
amendments may have substantial impact on as-
pects of data analysis and interpretability of trial
results. Thus, the amendments are often managed
carefully. On the other hand, since the costs of
conducting a clinical trial are growing enormously
while the probability of trial failure appears to be
high, the concept of design adjustments has re-
cently been expanded to formal design adapta-
tion during the course of the trial, following the
seminal work of Bauer and Köhne.1 In recent
decades, numerous adaptive methods have been
proposed in the statistical literature.2,3
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The concept of adaptation of trial design during the course of a clinical trial has recently drawn much 
interest from the pharmaceutical industry. The interest arises partly because statistical decision trees 
employed to address multiple complex clinical hypotheses within a clinical trial are increasingly complex,
and the statistical information generated from learning data prior to designing the trial is often insuffi-
cient to provide informative guidance for planning a pivotal trial. While the conventional fixed designs,
which usually permit no modification influenced by the internal trial data of key design specifications,
often cannot cover the range of complex statistical decision trees that must be prespecified in the study
protocol, it seems natural to consider modifications of trial design at some point in the trial. In regulatory
practice, some adjustments to study protocols are mostly made known to regulatory agencies in the form
of so-called protocol amendments. However, such design modifications may demand careful considera-
tion in dealing with any biases that may be caused by the adaptation, and may impede the interpretability
of trial results. [J Formos Med Assoc 2008;107(12 Suppl):S14–S18]
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This paper aims to provide a critical look at
the concept of mid-term design adaptation and to
articulate what is necessary for this adaptation.
Current Standard Trial Design
Conventional standard designs for pivotal regis-
tration trials require fixation of maximum sam-
ple size or the quantity of statistical information,
regardless of whether or not the trial is allowed
to terminate early. Moreover, most of the design
elements are required to be fixed; if necessary at
all, mid-term changes to the design elements are
normally very minimal. The requirements are to
facilitate valid statistical inference in terms of
testing and estimating treatment effects and, above
all, to protect trial integrity so as to minimize 
the bias caused by trial conduct for statistically
significant results to be interpretable.
In most of the current drug development pro-
grams, there is limited information available for
planning the pivotal registration clinical trials. The
learning trials prior to the pivotal registration tri-
als are small or uninformative and provide little
useful information to help plan the registration
trials. As a consequence, the primary efficacy vari-
ables can be difficult to select, effect sizes can be
difficult to postulate, and dropout response pro-
files are difficult to explore. Thus, no useful guid-
ance on how to handle missing data can be
obtained. In addition, there are few safety data on
human subjects and a clinically meaningful treat-
ment effect may not be available for realistically
planning the quantity of statistical information
necessary to ensure that the pivotal trial has a
reasonably good chance of detecting a meaning-
ful treatment effect.
Under the current clinical trial paradigm, the
number of pivotal registration trials is not fixed
and depends entirely on the drug sponsor. As a
result, the concept of type I (or false positive) error
rate may be unclear. At the very least, the type I
error rate associated with each clinical/statistical
hypothesis under testing needs to be controlled at
a small level (usually, much smaller than two-sided
5%). However, this is usually not sufficient. Within
each trial, the family-wise type I error rate also
needs to be properly controlled (usually smaller
than two-sided 5%). This statistical standard for
level of evidence is important, partly to make it fair
to all regulated drug sponsors. Nonetheless, is
controlling the family-wise type I error rate within
each trial sufficient? Should a type I error rate for
each indication be of concern? Another standard
pertains to the usual requirement that the positive
findings from a pivotal trial be replicated in an
independent trial. Thus, it is important to define
a trial in terms of controlling the family-wise
type I error rate associated with multiple analyses
or inferences within a trial.
Why Adaptation?
Many researchers have developed an increasing
interest in adapting clinical trial design, such as
interim modification of the design (e.g. sample
size or total number of events) within a trial, or
combining phase II and phase III (or pivotal reg-
istration) trials, i.e. combining the learning and
confirming phases into one trial. An example of
combining learning and confirming phases is
the exploration and selection of doses in the first
phase of the trial and testing the selected doses
in the second phase, but incorporating data from
both phases in the analysis.
The adaptation is expected to make mid-study
changes to maximize the chance of success or
possibly rescue a hopeful trial, combine phases to
reduce the time between phases for economic rea-
sons, and increase the number of study patients
who are likely to respond or less likely to experi-
ence toxicity. However, the perceived or expected
benefits versus costs/risk with the design adapta-
tions have not been well studied.
Some Regulatory Experiences
There are still relatively few regulatory submissions
using adaptive designs. The proposed design
adaptations are mostly an extension of the quan-
tity of statistical information such as sample size
and total number of targeted events, dropping a
treatment arm such as a dose of the test drug,
changing the primary endpoint such as a compos-
ite endpoint of major adverse clinical events, and
changing the study objective from superiority to
noninferiority in active controlled trials. At pres-
ent, very few cases using these adaptive designs
are accepted for pivotal trial settings.
For sample size re-estimation based on the ef-
fect size observed at an interim analysis, the sta-
tistical methods proposed in the literature, such
as the weighted Z test and p value combination
methods, are still controversial. Some question
whether weighting patient cohorts unequally 
before and after the adaptation is logical. The
unadjusted Z statistic requires adjustment of the
rejection region for ascertaining statistical signif-
icance, but the adjustment forces the rejection re-
gion to depend on the value of the Z statistic used
for sample size adaptation, and hence prespecifi-
cation of a fixed region is not possible. The deci-
sion criterion, such as conditional power, based
on the interim observed effect size can be very
unreliable.4 Other issues are: (1) how to deter-
mine the weight in the weighted Z statistics if
used; and (2) how to postulate a new effect size
for adjusting sample size. Another issue concerns
the need to tell all parties, including regulatory
authorities, about the possible sample size re-
estimation. In practice, it is rarely acceptable not
to tell regulatory authorities. On the other hand,
if the sample size adjustment criterion is com-
pletely specified, a more efficient fixed informa-
tion design can be devised. What, then, is the point
of using sample size adaptation? The controver-
sies have raised the issue of why and where to use
sample size adaptive designs.
The CAPRICORN trial is a controversial case in
which the primary endpoint was changed in the
mid-course of the trial.5 The original plan of using
a single primary endpoint of all-cause mortality
was modified to include the composite endpoint
of all-cause mortality or cardiovascular hospital-
ization as the first primary endpoint, and make
all-cause mortality the second primary endpoint.
An α allocation was also made to accommodate
this change. The trial failed to draw a definitive sta-
tistical conclusion about the drug effects on these
two endpoints. Had the change not been made, the
originally intended all-cause mortality would have
been statistically significant in favor of the drug.
The lesson has been learned in this case. Hung et al2
also noted that there is no theoretical basis for an
adaptive change of endpoint to be more statisti-
cally efficient than the nonadaptive design that
does not change the endpoint throughout a clini-
cal trial. On the other hand, as the number of (pri-
mary and secondary) endpoints increases, it will
clearly be harder, particularly under the conven-
tional nonadaptive designs, to prospectively devise
a statistical significance decision tree that can opti-
mize the statistical efficiency with proper inferences
for the endpoints in many possible scenarios.
Adverse Effects with Design Adaptation
In conventional nonadaptive designs without
any interim analysis, a widely employed statistical
method for formally testing secondary endpoints
is the so-called hierarchical testing strategy, by
which, if the primary endpoint achieves statistical
significance at the targeted α level (usually two-
sided 5%), the secondary endpoints can be tested
in a prespecified hierarchical order at the same 
α level for each endpoint, until the nominal 
p value is larger than the α level for the previous
tested endpoint. However, when the primary end-
point is tested more than once, e.g. under a group-
sequential design,6–8 the primary endpoint is
tested according to the prespecified α spending
rule, and testing any subsequent secondary end-
points becomes difficult. The aforementioned
hierarchical testing strategy is no longer statisti-
cally valid in the sense that the false-positive rates
for any subsequent secondary endpoints exceed
the acceptable α level. This problem has been 
reported by Hung et al.9 Furthermore, beyond
the group sequential design, sample size adapta-
tion will increase the false-positive rate of any
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secondary endpoint even more, and the adaptive
test cannot handle this problem properly.
Logistic Issues
The most challenging problem with any adaptive
designs, including the conventional group sequen-
tial designs, is whether the trial that employs
such a design can be free from any bias that may
be due to possible trial misconduct caused by
knowledge of any interim data. This type of bias
cannot be properly handled by adjusting statisti-
cal analyses and will hamper interpretability of
the trial results. The logistic issues include those
of implementation of design adaptations, com-
pliance with the standard operating procedure,
and maintenance of confidentiality.
Implementation of any kind of design adap-
tations involves deciding which party will conduct
the adaptation, who will see any interim data,
what knowledge of internal trial data to protect
from investigators, assessors, patients and com-
pany management, and how to minimize any 
influence of adaptation on the behavior of inves-
tigators or patients.
Assessment of compliance with the standard
operating procedure requires serious assessment
of the ability to comply, how to ensure compliance,
how to check and monitor quality of compliance,
paper trails about compliance data, and “carrots”
for compliance and “sticks” for noncompliance.
Confidentiality pertains to the internal con-
stituents as well as external communities, and the
ability to mask. External communities such as stock
investors often have a huge influence on whether
a trial can proceed or whether it will be forced to
change its course in any shape or form, particularly
after internal trial data have been leaked.
Concluding Remarks
Conventional fixed designs that usually permit no
change in the key design specifications have pre-
sented good trial design models for pivotal clinical
trials, which provide the basis for regulatory deci-
sion making. It is also recognized that such designs
are frequently too simple to embrace many rea-
sonable statistical decision trees when they are
complex and must be prespecified in the study pro-
tocol. In regulatory practice, some adjustments to
the study protocol are usually made known to reg-
ulatory agencies in the form of so-called protocol
amendments. The concept of design adaptation
seems natural to offer intuitively appealing alterna-
tive designs. However, such designs still have a long
way to go before becoming usable in terms of abil-
ity to achieve the intended goals. Many related
logistic issues require further extensive research.
Adaptive designs may be experimented with in
learning trials to gain experience in better explor-
ing drug effects without excessive false-positive
results, better understanding the ability to properly
implement such designs, and testing the review-
ability of such design trials by regulatory agencies.
Extension of the kind of clinical trial simulations
performed frequently by statistical scientists is
needed at the design planning stage, to explore
the feasibility and efficiency of such designs.
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